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including age, gender, body mass index. diabetes, hypertension. angina, previous myo- 
cardial infarction, previous CABG, previous PTCA, and valvular disease. Correlation by 
univariate and multivariate analysis was determined for each of these characteristics with 
PWV. Results: Arterial stiffness by PWV measurements correlated strongly and inde- 
pendently with age and hypertension (pcO.0001 and p<O.O250, respectively). Coronary 
artery disease as defined by angicgraphy as present or absent, as obstructive or non- 
obstructive, and as three vessel or less than three vessel disease, did demonstrate a sig- 
nificant correlation with PWV measurements in univariate analysis (p=O.O095). However, 
in multivariate analysis with correction for age and blood pressure, PWV was not a signif- 
icant predictor of the presence and severity of coronary atherosclerosis (p=O.9968). The 
presence of diabetes and of elevated homocystelne levels did also show a statistically 
significant and independent correlation with PWV (p=O.O204 and p=O.O061, respec- 
tively). Conclusion: Arterial stiffness by PWV measurements correlates well with age, 
hypertension, diabetes and homocysteine levels, but does not independently predict the 
presence or severity of coronary artery disease. 
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Background: Aortic stiffness, an independent risk factor for cardiovascular disease, can 
be assessed noninvasively by measuring aortic pulse wave velocity (PWV). The tech- 
nique is easy and reproducible, and this is reflected in its widespread use in clinical stud- 
ies. However data are lacking on its comparison with invasively derived PWV Our aim is 
to compare noninvasive aortic PWV (NIX-PWV) with invasive aortic PWV (Ix-PWV). 
Methods: 15 patients undergoing elective coronary angioplasty underwent NIX-PWV 
assessment that morning with the Sphygmacor Pulse Wave AnalysisTM system. All vaso- 
active drugs had been withheld. Noninvasive transit distance (NIX-D), the estimated dis- 
tance traveled by the pressure wave in the aorta, was measured over the body surface 
from the sternal notch to the femoral pulse. Noninvasive transit time (NIX-T) was obtained 
using electrocardiogram (ECG) gated pressure traces recorded from sequential carotid- 
femoral artery tonometry. Prior to intervention, an angioplasty guide wire with a pressure 
sensor tip (RADI PressureWireTM) was positioned in the aortic root and then in the femo- 
ral artery, to obtain ECG gated pressure traces for calculation of the invasive transit time 
(Ix-T). The aortic root-femoral pullback distance (Ix-D) was marked on the wire. Noninva- 
sive and invasive measurements were repeated 3 times. Noninvasive blood pressure 
was recorded at the time of all measurements. PWV was calculated as: DIT m/s. 
Results: NIX-PWV correlated with Ix-PWV after correcting for mean arterial pressure (R= 
0.73, p<O.Oi). However, there was a mean difference between them of 1.3 m/s (14% of 
absolute mean) with a considerable variation in this difference, the standard deviation 
(SD) of the diflerence being 1.8 m/s (20%). There was also a difference between NIX-D 
and Ix-D, the mean difference being 70 mm (12% of absolute mean) and the SD of the 
difference, 39 mm (7%). 
Conclusion: Noninvasive aortic PWV can be used as an index of aortic stiffness. How- 
ever it varies considerably with invasive PWV. This may partly be due to errors in esti- 
mating noninvasIve transit distance. Thus, refining the technique may further increase 
the power of this tool to predict adverse cardiovascular outcome. 
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Introduction: Central arterial compliance is an independent risk factor for mortality 
whereas matters concerning peripheral arterial compliance and effect of different treat- 
ments are unsettled. 
Methods: Fifty-six patients (24 females) from the LIFE study aged 69 years (55-80) with 
ECG-determined LVH were examined after 14 days on placebo treatment and again 
after 1 year of treatment with either losartan or atenolol in equipotent dosages. Brachial 
artenal compliance was measured using a volume-oscillometric method (Artcomp, Cri- 
tikoti). 
Results: BP was 163+21/89+15 mmHg at baselme and 154*18/81+12 mmHg after 1 
year and was similar in the treatment arms (ns). Isobaric compliance decreased after 1 
year (~~0.05) but was still elevated compared to matched controls (p=O.O02). Compli- 
ance at MAP was unchanged (ns). No difference was seen according to treatment after 
adlusting for gender, age and body surface area (IX). 
Conclusions: Brachlal artery compliance is maintained normal, only at a higher BP in 
hypertension accompanied by LVH. Isobaric brachial compliance decreases towards 
normal after 1 year of treatment, apparently irrespective of treatment with losartan or 
atenolol. 
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Background: Atherosclerosis-related mechanisms may play a role in aortic dilatation 
and aneurysm formation. We examined whether infection with Chlamydia pneumoniae 
(Cpn), a pathogen presumably involved in atherogenesis, IS associated with thoracic aor- 
tic dilatation in a sample of the general population. Methods: Thoracic aortic dimensions 
(diameters at the sinuses of Valsalva [SV], ascending aorta [AA], aoRic arch, and 
descending aorta [DA]) were measured by transesophageal echocardlography in 373 
subjects (median age 66 yr, range 51.101; 52% men) participating I” a population-based 
study (SPARC: Stroke Prevention -Assessment of Risk in a Community), who were free 
of significant aortic valve disease. The association between Cpn IgG seropositivity and 
aortic dimensions was examined in 372 subjects (a single subject with positive IgM anti- 
bodies, indicating acute Cpn infection, was excluded from analysis). Results: Age, male 
gender, and body surface area (BSA) were significant determinants of aortic diameters, 
jointly accounting for 41% 31%, 38% and 47% of the variability in aoflic diameter at the 
SV (mean diameter f SD: 33.7q3.8 mm), AA (33.323.8 mm), aortic arch (27.4i2.8 mm), 
and DA (25.99.0 mm), respect&y. Cpn antibodies (titers ,1:16) were present in 274 
subjects (74%): low titers (1:16-1:32) in 57 (15%), intermediate titers (1:64-1:128) in 137 
(37%), and high titers (21:256) in 80 subjects (22%). Cpn titers were not associated with 
the diameter of the SV (f=O.79). AA (EO.96) aortic arch (EO.58), and DA (EO.51). 
adjusting for age, sex. BSA. and smoking status (Pvalues are for the joint inclusion of all 
Cpn titer levels in the respective models). Conclusions: Cpn seropositwity is not associ- 
ated with thoracic aortic dilatation in the general population. These findings do not sup- 
port a role for Cpn infection in the pathogenesis of thoracic aortic dilatation and, 
probably, in aortic aneurysm formation. 
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Background: Sildenafil (S) is an effective drug for erectile dysfunchon affecting the nitnc 
oxide-cGMP pathway. Wave reflection is an Important index of arterial stiffening and car- 
diac afterload and has been inversely associated with exercise capacity. 
Methods: To investigate the effect of S on cardiac function and wave reflection in con- 
gestive hearl failure (CHF) we studied 20 pts (age 48-88 yrs) in NYHA class II or (II 
(EF<35%), in a randomized, double-blind, placebo-controlled, cross-over design (50 mg 
of S and placebo). Wave reflection was studied by measuring augmentation index (Alx) 
using a validated system (SphygmoCoa) that employs high-fidelity artenal tonometry 
and pulse wave analysis. Cardiac output was measured by echocardiography. 
Results: S was well tolerated with no side effects in any patlent S led to a increase in 
cardiac index (by 0.38 Ilminim2, PcO.0001. graph). This was associated with. and attrib- 
utable to, a decrease in left ventricular load (aortic and left ventricular systolic pressure 
fell by 13.9 mmHg, PcO.0001). Alx was decreased by 3.5% (P<O.OOOl; graph) indicating 
reduced wave reflection from peripheral sites. Total systemic resistance fell by 478.5 
dynes-secwm~5 (p<O.OOOl; graph). 
Conclusions: S leads to an Improvement in cardiac function in CHF patients which is 
associated with a favorable effect on central and penpheral a&anal properties. This has 
important implications for the therapeutic profile of the drug in patients with compromised 
cardiac performance. 
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